ERBB2 and breast neoplasm: Our results demonstrated that FGFR1/2/3 genomic alterations, primarily FGFR1 amplification, were present in approximately 20% of HR + HER2− breast tumors, 23.8% of HER2+ breast tumors, and 24% of TNBC.